On the AAV biology front, the lab focuses on advancing studies in human-relevant and disease-relevant settings. The team’s research interests include AAV genome persistence, the functional roles of inverted terminal repeats (ITRs), development of an AAV atlas in human tissues (H2H program), and the exploration of non-viral delivery approaches.
Embedded Files
A major disease-oriented focus of the lab is the development of gene therapy solutions for Fuchs endothelial corneal dystrophy (FECD). The lab’s research addresses both early-onset and late-onset forms of FECD, with therapeutic strategies encompassing gene augmentation, gene modulation, and gene editing.
The lab values and actively fosters meaningful collaborations to advance scientific discovery and therapeutic development. It has established a strong collaborative network, including close partnerships with cornea surgeons and ophthalmologists within the department, as well as active collaborations with local and national eye banks to obtain ocular tissues for research. The lab also works closely with Dr. Menying Hu’s group on non-viral delivery strategies for ocular diseases and collaborates with external academic and industry partners.
Page updated
Google Sites
Report abuse